MEROFLIP / MERONIF / MEROFIN INJECTION

Brand Name : Meroflip / Meronif / Merofin

Generic Name : Meropenem Injection IP

Pack Size : Vial + WFI

Dosage Form : Powder for Injection

Strength : 500 mg & 1 gm

Therapeutic indications : Meropenem is indicated for the treatment of the following infections in adults and children aged 3 months and older:
• Severe pneumonia, including hospital and ventilator-associated pneumonia.
• Broncho-pulmonary infections in cystic fibrosis
• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Intra- and post-partum infections
• Complicated skin and soft tissue infections
• Acute bacterial meningitis
Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Pharmacotherapeutic group : antibacterials for systemic use, carbapenems

ATC code : J01DH02

Pharmacodynamic properties : Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).
Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC (T>MIC) has been shown to best correlate with efficacy. In preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40% of the dosing interval. This target has not been established clinically.